Holistic Approach to Women’s Health and Pregnancy to be Discussed in Valley

Breaking News
717

Translate to Spanish or other 102 languages!

Mega Doctor News

- Advertisement -

Nurse Midwives, Nurse Practitioner to speak during free “Dessert with the Nurse” event Wednesday
at Valley Baptist in Harlingen

HARLINGEN – Two nurse midwives and a nurse practitioner will speak and answer questions on “Motherhood and Beyond:  Pregnancy, Delivery and Take Caring of the Whole You: A Holistic Approach”, during a free “Dessert with the Nurse” event this Wednesday, August 12 at 6:30 p.m. at Valley Baptist Medical Center, 2101 Pease Street in Harlingen (on the first floor of the hospital, in the Woodward Conference Center).

The speakers will include Nivia Fisch, FACNM, a Fellow in the American College of Nurse-Midwives; Susan Boone, MSN, CHM, RN, Certified Nurse Midwife; and Belinda Ramirez, MSN, WHNP-BC, Women’s Health Nurse Practitioner.

- Advertisement -

The event is free and open to the community and will include a complimentary heart-healthy dessert.  For more information and to RSVP, please call 1-888-902-5433.

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Summertime Senior Expo
Next article
UTRGV professors connect student-centered teaching methodology with Apple technology

More Articles

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

Embolism Treatment Developed at University of Michigan receives FDA clearance 

Patients with persistent blood clots require frequent medical interventions just to survive. Yet despite this critical need, there have been few advancements in how these patients are treated. 

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.
- Advertisement -